Aapro, Matti
Karthaus, Meinolf
Schwartzberg, Lee
Bondarenko, Igor
Sarosiek, Tomasz
Oprean, Cristina
Cardona-Huerta, Servando
Hansen, Vincent
Rossi, Giorgia
Rizzi, Giada
Borroni, Maria Elisa
Rugo, Hope
Funding for this research was provided by:
Helsinn
Article History
Received: 14 May 2016
Accepted: 25 September 2016
First Online: 24 November 2016
Compliance with ethical standards
:
: The authors have the following conflicts of interest to disclose:Aapro: consultant for Helsinn Healthcare, Eisai, Tesaro, and Merck; research funding from Helsinn Healthcare; speaker’s bureau for Helsinn Healthcare, Taiho, Eisai, Tesaro and Merck.Karthaus: consultant for Helsinn Healthcare.Schwartzberg: consultant for Helsinn Healthcare and Tesaro; research funding from Helsinn Healthcare.Bondarenko: nothing to disclose.Sarosiek: research funding from Helsinn Healthcare, Novartis, Parexel, Celltrion, Quintiles, Samsung, Lilly, Astra Zeneca, <b>and</b> GSK.Oprean: consultant for Boehringer Ingelheim and MSD; honoraria received from Amgen, Sandoz, Astra Zeneca, Pfizer, and Lily.Cardona-Huerta: travel/accommodations from Roche.Hansen: nothing to disclose.Rossi, Rizzi, and Borroni: employees of Helsinn Healthcare.Rugo: research funding to University of California San Francisco from Eisai